Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Leukemia, Lymphoma
About this trial
This is an interventional treatment trial for Leukemia focused on measuring recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia
Eligibility Criteria
DISEASE CHARACTERISTICS: Immunohistopathologically documented relapsed or refractory CD20+ indolent lymphomas or mantle cell lymphoma Indolent B-cell lymphomas including any of the following subtypes: Follicular lymphoma (grade I, II, or III) Small lymphocytic lymphoma or chronic lymphocytic leukemia Marginal zone lymphoma (splenic, nodal, and extra-nodal) Lymphoplasmacytoid lymphoma Ineligible for or unwilling to participate in other FHCRC/UWMC protocols Serological evidence of prior exposure to Epstein-Barr virus Must agree to undergo peripheral blood drawing, bone marrow biopsy, lymph node biopsy, and nuclear medicine imaging Must agree to cytoreductive chemotherapy if necessary to reduce lymph nodes to < 5 cm in diameter or circulating B lymphocyte counts to < 5,000/mm^3 No pulmonary involvement No CNS involvement PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: At least 90 days Hematopoietic: Not specified Hepatic: No active hepatitis B infection Renal: Not specified Other: No HIV positivity Not pregnant or nursing Fertile patients must use effective contraception No history of hypersensitivity reactions to murine proteins PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 months since prior rituximab, tositumomab, or ibritumomab No prior allogeneic stem cell transplantation No other concurrent immunotherapy (e.g., interferons, vaccines, or other cellular products) Chemotherapy: At least 2 years since prior fludarabine or cladribine At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: No concurrent systemic corticosteroids except to treat toxicity from chemotherapy or cellular immunotherapy Radiotherapy: Not specified Surgery: Not specified Other: At least 4 weeks since prior immunosuppressive therapy and recovered No concurrent pentoxifylline No other concurrent investigational agents
Sites / Locations
- City of Hope Comprehensive Cancer Center
- Fred Hutchinson Cancer Research Center
- University of Washington School of Medicine